Results 11 to 20 of about 4,022 (166)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

Microbiology Spectrum, 2022
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019).
James A. Karlowsky, Andrew J. Walkty, Melanie R. Baxter, Heather J. Adam, Philippe R. S. Lagacé-Wiens, Frank Schweizer, Denice Bay, Joseph P. Lynch, Michael R. Mulvey, George G. Zhanel   +9 more
doaj   +1 more source

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

Microbiology Spectrum, 2022
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia ...
Dee Shortridge, Jennifer M. Streit, Rodrigo Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway

Journal of Global Antimicrobial Resistance, 2023
: Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert, Laura Berneking, Anna Both, Benjamin Berinson, Jiabin Huang, Martin Aepfelbacher, Christine Wolschke, Dominic Wichmann, Holger Rohde   +8 more
doaj   +1 more source

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations

IDCases, 2020
Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel, Jeffrey M. Steele, Scott W. Riddell, Zachary Jones, Pegah Shakeraneh, Timothy P. Endy   +5 more
doaj   +1 more source

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant, Abid Hussain, Malcolm Bain, Christopher Longshaw, Anne Santerre Henriksen   +4 more
doaj   +1 more source

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients

Pharmaceutics, 2022
Background: Cefiderocol is a siderophore cephalosporin antibiotic active against Gram-negative bacteria, including extended-spectrum beta-lactamase and carbapenemase-producing strains.
Noël Zahr, Saik Urien, Benoit Llopis, Gaëlle Noé, Nadine Tissot, Kevin Bihan, Helga Junot, Clémence Marin, Bochra Mansour, Charles-Edouard Luyt, Alexandre Bleibtreu, Christian Funck-Brentano   +11 more
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen, Anne Santerre Henriksen, Christopher Longshaw, Yoshinori Yamano, Ben Caldwell, Axel Hamprecht   +5 more
doaj   +1 more source

Mechanism of action of cefiderocol

Revista Española de Quimioterapia, 2022
Gram-negative bacilli are intrinsically resistant to many antibiotics due to the low permeability of their outer membrane. The most effective strategy to solve this problem has been the design of antibiotics that cross the membrane using specific transport systems.
Soriano, Alex, Mensa, Josep
openaire   +2 more sources

Antibacterial spectrum of cefiderocol

Revista Española de Quimioterapia, 2022
Cefiderocol, a siderophore catechol cephalosporin, recently introduced in the market has been developed to enhance the in vitro activity of extended spectrum cephalosporins and to avoid resistance mechanisms affecting cephalosporins and carbapenems. The in vitro study of cefiderocol in the laboratory requires iron depleted media when MIC values are ...
Cordero, Desirée Gijón, Castillo-Polo, Juan Antonio, Ruiz-Garbajosa, Patricia, Canton, Rafael   +3 more
openaire   +2 more sources

Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract

Therapeutic Advances in Urology, 2022
Cefiderocol is a unique siderophore cephalosporin antimicrobial agent that has shown promise in treating complicated urinary tract infections (cUTI). Urinary tract infections are commonly diagnosed infections with risk increasing with age and prevalence ...
Hongmei Wang, Brittany N. Palasik
doaj   +1 more source